



## Mid Atlantic Regional Chapter of the American College of Sports Medicine

45<sup>th</sup> Annual Scientific Meeting, November 4<sup>th</sup>- 5<sup>th</sup>, 2022  
Conference Proceedings

International Journal of Exercise Science, Issue 9, Volume 11



### PGC-1 $\alpha$ Overexpression Improves Angiogenic Signaling Potential of Skeletal Muscle-derived Extracellular Vesicles

Chris K. Kargl<sup>1,2</sup>, Brian P. Sullivan<sup>1</sup>, Derek Middleton<sup>1</sup>, Andrew York<sup>1</sup>, Landon Burton, Jeffrey J. Brault<sup>3</sup>, Shihuan Kuang<sup>1</sup>, Timothy P. Gavin<sup>1</sup>. <sup>1</sup>Purdue University, West Lafayette, Indiana, USA, <sup>2</sup>University of Pittsburgh, Pittsburgh, Pennsylvania, USA, <sup>3</sup>Indiana University School of Medicine, Indianapolis, IN, USA.

**PURPOSE:** Skeletal muscle capillary densities are proportional to muscle fiber mitochondrial contents and oxidative capacity. Muscle cells secrete numerous factors that regulate neighboring capillary endothelial cells (EC), including extracellular vesicles (SkM-EV). Peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1 $\alpha$ ) is a key regulator of mitochondrial biogenesis and the oxidative phenotype in skeletal muscle and is a molecular driver of adaptations to exercise. Skeletal muscle PGC-1 $\alpha$  regulates secretion of multiple angiogenic factors, but it is unknown whether PGC-1 $\alpha$  regulates the angiogenic signaling potential of SkM-EVs. **METHODS:** PGC-1 $\alpha$  was overexpressed via adenovirus in primary human myotubes. EVs were collected from PGC-1 $\alpha$  myotubes (PGC1-EV) as well as from myotubes treated with a GFP adenoviral control (GFP-EV) and from untreated myotubes (CON-EV). Human umbilical vein endothelial cells (HUVEC) were treated with EVs (10  $\mu$ g/ml) and *in vitro* angiogenic responses were analyzed. To determine if PGC-EVs are protective against oxidative stress, HUVECs were treated with 200  $\mu$ M H<sub>2</sub>O<sub>2</sub> following EV treatments *in vitro* angiogenic responses were analyzed. Significance:  $P \leq 0.05$ . **RESULTS:** PGC-EV treatment of cultured human umbilical vein endothelial cells (HUVEC) increased HUVEC proliferation (+36.6%), tube formation (length: +28.1%; number: +25.7%), cellular viability (+52.9%), and reduced reactive oxygen species levels (-41%) compared to GFP-EV. Additionally, PGC-EV treatment improved tube formation (length: +52.8%; number: +57%) and reduced cellular senescence (-30.1%) following acute oxidative stress compared to GFP-EV treatment. **CONCLUSIONS:** This report demonstrates that overexpression of PGC-1 $\alpha$  in human myotubes increases the angiogenic potential of skeletal muscle EVs. These angiogenic benefits coincided with greater protection against H<sub>2</sub>O<sub>2</sub> induced reductions in tube formation and increases in cellular senescence. Increases in PGC-1 $\alpha$  expression in skeletal muscle may prompt the release of SkM-EVs that support vascular redox homeostasis and angiogenesis.